PubRank

Christian J Buchholz

Author PubWeight™ 32.37‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Targeted cell entry of lentiviral vectors. Mol Ther 2008 2.34
2 T-cell receptor gene transfer exclusively to human CD8(+) cells enhances tumor cell killing. Blood 2012 1.55
3 Specific gene delivery to liver sinusoidal and artery endothelial cells. Blood 2013 1.51
4 Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors. Nat Methods 2010 1.48
5 Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases. Cancer Res 2006 1.12
6 DARPins: an efficient targeting domain for lentiviral vectors. Mol Ther 2011 1.08
7 Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus. Cancer Res 2013 1.05
8 Lentiviral vectors targeted to MHC II are effective in immunization. Hum Gene Ther 2011 1.02
9 Restriction of measles virus RNA synthesis by a mouse host cell line: trans-complementation by polymerase components or a human cellular factor(s). J Virol 2002 0.98
10 Selection of functional human antibodies from retroviral display libraries. Nucleic Acids Res 2005 0.97
11 The proline-rich region of the ecotropic Moloney murine leukaemia virus envelope protein tolerates the insertion of the green fluorescent protein and allows the generation of replication-competent virus. J Gen Virol 2003 0.97
12 Circumventing tolerance to the prion protein (PrP): vaccination with PrP-displaying retrovirus particles induces humoral immune responses against the native form of cellular PrP. J Virol 2005 0.94
13 Identification of R-peptides in envelope proteins of C-type retroviruses. J Gen Virol 2002 0.93
14 Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer. Mol Ther 2012 0.92
15 Chronic gene delivery of interferon-inducible protein 10 through replication-competent retrovirus vectors suppresses tumor growth. Cancer Gene Ther 2005 0.91
16 Targeted retroviral vectors displaying a cleavage site-engineered hemagglutinin (HA) through HA-protease interactions. Mol Ther 2006 0.89
17 DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety. Mol Ther 2013 0.88
18 Manufacturing and quality control of cell-based tumor vaccines: a scientific and a regulatory perspective. J Immunother 2006 0.87
19 Vesicular stomatitis virus glycoprotein displaying retrovirus-like particles induce a type I IFN receptor-dependent switch to neutralizing IgG antibodies. J Immunol 2007 0.86
20 Vaccination with Abeta-displaying virus-like particles reduces soluble and insoluble cerebral Abeta and lowers plaque burden in APP transgenic mice. J Immunol 2009 0.85
21 Directed evolution of retrovirus envelope protein cytoplasmic tails guided by functional incorporation into lentivirus particles. J Virol 2005 0.85
22 Measles virus glycoprotein-based lentiviral targeting vectors that avoid neutralizing antibodies. PLoS One 2012 0.85
23 Liver cancer protease activity profiles support therapeutic options with matrix metalloproteinase-activatable oncolytic measles virus. Cancer Res 2010 0.82
24 The receptor attachment function of measles virus hemagglutinin can be replaced with an autonomous protein that binds Her2/neu while maintaining its fusion-helper function. J Virol 2013 0.82
25 Resting lymphocyte transduction with measles virus glycoprotein pseudotyped lentiviral vectors relies on CD46 and SLAM. Virology 2011 0.80
26 Cell type specific gene delivery by lentiviral vectors: New options in immunotherapy. Oncoimmunology 2013 0.80
27 CD19 and CD20 targeted vectors induce minimal activation of resting B lymphocytes. PLoS One 2013 0.80
28 Envelope proteins of spleen necrosis virus form infectious human immunodeficiency virus type 1 pseudotype vector particles, but fail to incorporate upon substitution of the cytoplasmic domain with that of Gibbon ape leukemia virus. J Gen Virol 2006 0.79
29 Replicating retroviral vectors mediating continuous production and secretion of therapeutic gene products from cancer cells. Cancer Gene Ther 2005 0.79
30 Intrahepatic application of suicide gene-armed measles virotherapeutics: a safety study in transgenic mice and rhesus macaques. Hum Gene Ther Clin Dev 2013 0.79
31 CD105 is a surface marker for receptor-targeted gene transfer into human long-term repopulating hematopoietic stem cells. Stem Cells Dev 2015 0.77
32 Displaying epidermal growth factor on spleen necrosis virus-derived targeting vectors. Virology 2003 0.77
33 Fusoselect: cell-cell fusion activity engineered by directed evolution of a retroviral glycoprotein. Nucleic Acids Res 2006 0.75
34 Vaccination against prion diseases. Discov Med 2006 0.75
35 Escape from R-peptide deletion in a γ-retrovirus. Virology 2011 0.75
36 Cominatorial chemistry & high throughput screening. Editorial from Guest Editors. Comb Chem High Throughput Screen 2008 0.75
37 Erratum: Monitoring CAR T cell generation with a CD8-targeted lentiviral vector by single-cell transcriptomics. Mol Ther Methods Clin Dev 2022 0.75